NextCure, Inc (NXTC) insider trading

Every open-market stock purchase and sale by NextCure, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • ADAR1 Capital Management LLC (10% owner) bought $1.6M in the last 90 days, growing their stake 20%.

Last 12 months: insiders bought $1.6M (2 buys) and sold $0 (0 sales). Last close $5.78 on Aug 4, 2026.

Recent NXTC insider trades

DateInsiderTradeValue
Jul 31, 2026ADAR1 Capital Management LLC (10% owner)Bought$125K
Jul 31, 2026ADAR1 Capital Management LLC (10% owner)Bought$38.4K
Jul 31, 2026ADAR1 Capital Management LLC (10% owner)Bought$16.4K
Jul 30, 2026ADAR1 Capital Management LLC (10% owner)Bought$490K
Jul 30, 2026ADAR1 Capital Management LLC (10% owner)Bought$386K
Jul 30, 2026ADAR1 Capital Management LLC (10% owner)Bought$249K
Jul 30, 2026ADAR1 Capital Management LLC (10% owner)Bought$120K
Jul 30, 2026ADAR1 Capital Management LLC (10% owner)Bought$100K
Jul 29, 2026ADAR1 Capital Management LLC (10% owner)Bought$9.1K
Jul 29, 2026ADAR1 Capital Management LLC (10% owner)Bought$8K
Jul 28, 2026ADAR1 Capital Management LLC (10% owner)Bought$31.7K
Jul 27, 2026ADAR1 Capital Management LLC (10% owner)Bought$39K
Jun 18, 2026Elaine V Jones (Insider)Bought (not open market)—
Jun 18, 2026David S Kabakoff (Insider)Bought (not open market)—
Jun 18, 2026Anne Elizabeth Borgman (Insider)Bought (not open market)—
Jun 18, 2026Ellen Feigal (Insider)Bought (not open market)—
Jun 18, 2026John G Houston (Insider)Bought (not open market)—
Jun 18, 2026Stephen W Webster (Insider)Bought (not open market)—
Jan 30, 2026Udayan Guha (C-suite exec)Bought (not open market)—
Jan 30, 2026Steven P. Cobourn (CFO)Bought (not open market)—
Jan 30, 2026Kevin G. Shaw (VP)Bought (not open market)—
Jan 30, 2026Sourav Kundu (VP)Bought (not open market)—
Jan 30, 2026Michael Richman (CEO)Bought (not open market)—
Jan 30, 2026Timothy Mayer (COO)Bought (not open market)—

Who's trading NXTC

Get free alerts when an insider at NextCure, Inc files a new trade →